Zevra Therapeutics (ZVRA) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Zevra Therapeutics is scheduled to release its Q2 2025 earnings on August 12th, with analysts expecting earnings of $0.65 per share and revenue of $22.49 million.
• The company's last quarter saw an earnings per share of ($0.06), surpassing estimates significantly, while revenue reached $20.40 million, above the projected $16.96 million.
• Current institutional ownership stands at 35.03%, with recent activity including the purchase of 16,700 shares by Strs Ohio valued at approximately $125,000.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect Zevra Therapeutics to post earnings of $0.65 per share and revenue of $22.49 million for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter last year, the business earned ($0.40) EPS. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Trading Down 0.9%

NASDAQ ZVRA traded down $0.11 during trading hours on Friday, reaching $12.02. The company's stock had a trading volume of 985,927 shares, compared to its average volume of 1,114,547. The firm has a fifty day simple moving average of $10.42 and a 200-day simple moving average of $8.68. The stock has a market cap of $657.25 million, a P/E ratio of -6.33 and a beta of 1.87. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93.

Analyst Ratings Changes

A number of brokerages have commented on ZVRA. HC Wainwright began coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price target for the company. Cantor Fitzgerald boosted their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Finally, Wall Street Zen downgraded shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $23.71.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ZVRA. Strs Ohio purchased a new position in shares of Zevra Therapeutics in the 1st quarter worth about $125,000. Creative Planning purchased a new position in shares of Zevra Therapeutics in the 2nd quarter worth about $92,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after buying an additional 1,812 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.